SCHEMBL14948915

SCHEMBL14948915

CCc1ccc(-n2cccn2)c(F)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 1/20 0.43
MAPT P10636 3/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 2/20 0.42
LMNA P02545 2/20 0.42
GAA P10253 2/20 0.42
G6PD P11413 1/20 0.42
PKM P14618 1/20 0.41
NAMPT P43490 1/20 0.39
KCNN4 O15554 1/20 0.39
KCNA5 P22460 1/20 0.39
MAPK1 P28482 2/20 0.38
NPC1 O15118 1/20 0.38
ACLY P53396 2/20 0.38
ADRA1A P35348 2/20 0.37
USP9X Q93008 2/20 0.37
JAK2 O60674 1/20 0.36
TYK2 P29597 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13548288 0.88 PDE2A (0.42) PDE2AMAPTMEN1KMT2AKDM4E
SCHEMBL18865533 0.84 LMNA (0.47) PDE2AMAPTMEN1KMT2AKDM4E
SCHEMBL6879932 0.84 ALDH1A1 (0.42) PDE2AMAPTMEN1KMT2AKDM4E
SCHEMBL13547926 0.84 PDE2A (0.41) PDE2AMAPTMEN1KMT2AKDM4E
SCHEMBL21032124 0.81 MAPT (0.39) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL7031591 0.79 ALDH1A1 (0.46) PDE2AMAPTMEN1KMT2AKDM4E
SCHEMBL27612893 0.79 ALDH1A1 (0.41) PDE2AMAPTMEN1KMT2AKDM4E
SCHEMBL30038214 0.78 KCNN4 (0.52) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL4302034 0.78 KCNN4 (0.52) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL19823853 0.77 MAP2K2 (0.36) KDM4EALDH1A1LMNAGAAACLY

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140371223-A1 NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS ADDEX PHARMA S.A. (CH) 2014-12-18 US disclosed
US-8779129-B2 Triazinedione derivatives as GABAB receptor modulators ADDEX PHARMA S.A. (CH) 2014-07-15 US disclosed
US-20130123262-A1 NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS ADDEX PHARMA S.A. (CH) 2013-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140371223-A1 NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS CHRNA5, GABRA5, GABRB3 PDE2A 558/4885MAPT 2371/4885MEN1 4868/4885
US-20130123262-A1 NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS CHRNA5, GABRA5, GABRB3 PDE2A 558/4885MAPT 2371/4885MEN1 4868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.